-Report Cites the Potential of Immunomodulating Monoclonal Antibodies to Address Multiple Indications in Cancer and Chronic Inflammation-
-Lead Programs Out-licensed to Bristol-Myers Squibb and Novo Nordisk on Excellent Terms-
Report is Available for Download at: www.lifesciadvisors.com/clients/innate
NEW YORK, NY – April 18, 2012 – LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Innate Pharma, S.A. (Euronext: IPH.PA), a biotechnology company focused on the development of monoclonal antibodies (mAbs) in the innate immunity field. Innate Pharma has a strong pipeline of therapeutic immunomodulating mAbs, which includes lead candidates IPH21 and IPH22, targeting multiple indications in cancer and chronic inflammation, respectively. Both programs are currently in Phase I clinical trials. In particular, the IPH21 program out-licensed to BMS in 2011 constitutes the largest biotechnology licensing deal in France’s history. The agreement included a $35MM upfront payment, the potential for an additional $430MM for achieving certain pre-commercial milestones and double-digit royalty payments on net sales.
“We believe the recent BMS licensing agreement validates the potential of Innate Pharma’s technologies and the Company’s expertise in the area of innate immunity. If the recent successful launch of Yervoy (ipilimumab), the first commercialized immunomodulating antibody, is any indicator, BMS can contribute greatly to the successful development and commercialization of IPH21,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Like Yervoy, IPH21 has the potential to be a blockbuster oncology product with utility across multiple cancer types.”
In a 44-page Initiation Report by LifeSci Advisors, the clinical and business achievements of Innate Pharma thus far are listed and put into context. The Company’s immunomodulating mAbs, such as the IPH21 and IPH22 programs, aim to harness the body’s immune system in the fight against cancer and chronic inflammation diseases, respectively. IPH21 is a humanized anti-killer-cell immunoglobulin-like receptor (KIR) monoclonal antibody. The inhibition of the KIR receptor aims to activate natural killer (NK) cells, which in turn may promote the destruction of tumor cells and halt disease progression. IPH21 is currently in Phase I clinical trials. The second lead candidate for Innate Pharma is IPH22, which is a humanized anti-NKG2A mAb that promotes NK cell regulation of over-activated immune cells that play a role in inflammation and autoimmune disease. This mAb was out-licensed Novo Nordisk A/S and it is currently in Phase I clinical trials for the treatment of rheumatoid arthritis (RA).
Innate Pharma’s development pipeline also includes proprietary preclinical programs and the two main mAbs are: IPH33 and IPH41 for chronic inflammation and cancer, respectively. Additionally, the Company was involved with the groundbreaking discovery of NKp46 receptor regulatory mechanism, which might open a new avenue for immunomodulating therapies. Finally, the Company has strong research expertise and a portfolio of patents in the innate immunity space that makes it a desirable partner for any Pharmaceutical company seeking entry to the development of immunomodulatory drugs.
Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report’s full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA’s judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.